Last reviewed · How we verify

Combination - Tranilast and Febuxostat

Nuon Therapeutics, Inc. · Phase 2 active Small molecule

Combination - Tranilast and Febuxostat is a Antiproliferative agent, Xanthine oxidase inhibitor Small molecule drug developed by Nuon Therapeutics, Inc.. It is currently in Phase 2 development for Gout, Malignant hypertension.

Tranilast is a selective inhibitor of PDGF receptors, while Febuxostat is a xanthine oxidase inhibitor.

Tranilast is a selective inhibitor of PDGF receptors, while Febuxostat is a xanthine oxidase inhibitor. Used for Gout, Malignant hypertension.

At a glance

Generic nameCombination - Tranilast and Febuxostat
SponsorNuon Therapeutics, Inc.
Drug classAntiproliferative agent, Xanthine oxidase inhibitor
TargetPDGF receptor, Xanthine oxidase
ModalitySmall molecule
Therapeutic areaOncology, Cardiovascular
PhasePhase 2

Mechanism of action

Tranilast works by blocking the PDGF receptors, which are involved in the proliferation and migration of smooth muscle cells. Febuxostat, on the other hand, inhibits xanthine oxidase, an enzyme involved in the production of uric acid.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Combination - Tranilast and Febuxostat

What is Combination - Tranilast and Febuxostat?

Combination - Tranilast and Febuxostat is a Antiproliferative agent, Xanthine oxidase inhibitor drug developed by Nuon Therapeutics, Inc., indicated for Gout, Malignant hypertension.

How does Combination - Tranilast and Febuxostat work?

Tranilast is a selective inhibitor of PDGF receptors, while Febuxostat is a xanthine oxidase inhibitor.

What is Combination - Tranilast and Febuxostat used for?

Combination - Tranilast and Febuxostat is indicated for Gout, Malignant hypertension.

Who makes Combination - Tranilast and Febuxostat?

Combination - Tranilast and Febuxostat is developed by Nuon Therapeutics, Inc. (see full Nuon Therapeutics, Inc. pipeline at /company/nuon-therapeutics-inc).

What drug class is Combination - Tranilast and Febuxostat in?

Combination - Tranilast and Febuxostat belongs to the Antiproliferative agent, Xanthine oxidase inhibitor class. See all Antiproliferative agent, Xanthine oxidase inhibitor drugs at /class/antiproliferative-agent-xanthine-oxidase-inhibitor.

What development phase is Combination - Tranilast and Febuxostat in?

Combination - Tranilast and Febuxostat is in Phase 2.

What are the side effects of Combination - Tranilast and Febuxostat?

Common side effects of Combination - Tranilast and Febuxostat include Diarrhea, Nausea, Headache.

What does Combination - Tranilast and Febuxostat target?

Combination - Tranilast and Febuxostat targets PDGF receptor, Xanthine oxidase and is a Antiproliferative agent, Xanthine oxidase inhibitor.

Related